Sevoflurane is an inhaled anesthetic gas used to put patients to sleep during surgery and medical procedures. It helps keep patients unconscious and pain-free while doctors perform operations.[2] Ultane is currently approved and in use across 79 indications[4].[1]
Ultane is one of 1057 small molecule programs targeting Agitation. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
348 competitors in Prostate Cancer
Zoladex
Ultane
Talzenna
Tecentriq
Truqap
LHRH Agonist
Xaluritamig
Lutetium Lu-177 PNT2002
Lhrha
Luteinizing Hormone Releasing Hormone
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jun 7, 1995
ULTANE
NDA NDA020478
Jul 2, 1997
ULTANE
NDA NDA020478
Dec 23, 1997
ULTANE
NDA NDA020478
Aug 6, 1998
ULTANE
NDA NDA020478
Jun 16, 2000
ULTANE
NDA NDA020478
Mar 14, 2001
ULTANE
NDA NDA020478
Mar 30, 2001
ULTANE
NDA NDA020478
Aug 9, 2001
ULTANE
NDA NDA020478
Sep 28, 2001
ULTANE
NDA NDA020478
May 24, 2002
ULTANE
NDA NDA020478
Dec 11, 2002
ULTANE
NDA NDA020478
Jun 27, 2003
ULTANE
NDA NDA020478
Jun 21, 2005
ULTANE
NDA NDA020478
Jun 27, 2006
ULTANE
NDA NDA020478
Jan 21, 2010
ULTANE
NDA NDA020478
Aug 16, 2012
ULTANE
NDA NDA020478
Aug 16, 2012
ULTANE
NDA NDA020478
Mar 11, 2014
ULTANE
NDA NDA020478
Mar 11, 2014
ULTANE
NDA NDA020478
Oct 26, 2015
ULTANE
NDA NDA020478
Apr 27, 2017
ULTANE
NDA NDA020478
Mar 1, 2022
ULTANE
NDA NDA020478
Mar 1, 2022
ULTANE
NDA NDA020478
Mar 1, 2022
ULTANE
NDA NDA020478
Mar 1, 2022
ULTANE
NDA NDA020478
May 19, 2022
ULTANE
NDA NDA020478
Nov 1, 2022
ULTANE
NDA NDA020478
Feb 3, 2025
ULTANE
NDA NDA020478
Sources
Details